IP Library Granted Patent US 9,238,026
Granted Patent B2
US 9,238,026 · App. 14/110,391 · Granted Jan 19, 2016

Inhibitors of viral replication, their process of preparation and their therapeutical uses

Inventors: Sophie Chasset (Nandy, FR); Francis Chevreuil (Chantilly, FR); Benoit Ledoussal (Pommerit-Jaudy, FR); Frédéric Le Strat (Gagny, FR); Richard Benarous (Paris, FR)
Assignee: LABORATOIRE BIODIM
A61K31/405A61K31/427A61K31/436A61K31/4365A61K31/4743A61K31/538A61K45/06C07D209/18C07D209/24C07D333/24C07D333/60C07D407/04C07D413/04C07D417/04C07D491/052C07D495/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,238,026
App. No.
14/110,391
Granted
Jan 19, 2016
Kind
B2
Abstract

The present invention relates to compounds, their use in the treatment or the prevention of viral disorders, including HIV.

Claims (49)

1. A compound according to formula (D1),

wherein:

W represents a substituted aromatic heterocycle;

R 1 and R 7 each independently represent hydrogen, —CN, —OH, —O-cycloalkyl, —O-cycloalkenyl, —O-cycloalkynyl, —NH 2 , —NR 11 -cycloalkyl, —NR 11 -cycloalkenyl, —NR 11 -cycloalkynyl, —S-cycloalkyl, —S-cycloalkenyl, —S-cycloalkynyl, —COOH, —C(O)NH 2 , —CF 3 , —SO 2 NH 2 , —NHSO 2 NH 2 , —NHC(O)NH 2 , —OC(O)NH 2 , halogen, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, —O-aryl, —NR 11 -aryl, —S-aryl, arylalkyl, arylalkenyl, arylalkynyl, arylheteroalkyl, arylheteroalkenyl, arylheteroalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocycle, —O-heterocycle, —NR 11 -heterocycle, —S-heterocycle, heterocyclyl-alkyl, heterocyclyl-alkenyl, heterocyclyl-alkynyl, heterocyclyl-heteroalkyl, heterocyclyl-heteroalkenyl, or heterocyclyl-heteroalkynyl, non-substituted or substituted by at least one T 1 ,

wherein a carbon atom or a heteroatom of said alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, arylheteroalkyl, arylheteroalkenyl, arylheteroalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocycle, heterocyclyl-alkyl, heterocyclyl-alkenyl, heterocyclyl-alkynyl, heterocyclyl-heteroalkyl, heterocyclyl-heteroalkenyl, or heterocyclyl-heteroalkynyl can be oxidized to form a C═O, C═S, N═O, N═S, S═O or S(O) 2 ,

and wherein the aryl, arylalkyl, arylalkenyl, arylalkynyl, arylheteroalkyl, arylheteroalkenyl, arylheteroalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocycle, heterocyclyl-alkyl, heterocyclyl-alkenyl, heterocyclyl-alkynyl, heterocyclyl-heteroalkyl, heterocyclyl-heteroalkenyl, or heterocyclyl-heteroalkynyl group can be fused with at least one further cycle;

and wherein the alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl-alkyl, heterocyclyl-alkenyl, or heterocyclyl-alkynyl group can include one or more heteroatoms, selected from O, S and N, in the alkyl, alkenyl, or alkynyl moiety;

R 3 represents —O-cycloalkyl, —O-cycloalkenyl, —O-cycloalkynyl, —NR 11 -cycloalkyl, —NR 11 -cycloalkenyl, —NR 11 -cycloalkynyl, —S-cycloalkyl, —S-cycloalkenyl, —S-cycloalkynyl, C 4 -C 20 alkyl, C 4 -C 20 alkenyl, C 4 -C 20 alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, —O-aryl, —NR 11 -aryl, —S-aryl, arylalkyl, arylalkenyl, arylalkynyl, arylheteroalkyl, arylheteroalkenyl, arylheteroalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocycle, —O-heterocycle, —NR 11 -heterocycle, —S-heterocycle, heterocyclyl-alkyl, heterocyclyl-alkenyl, heterocyclyl-alkynyl, heterocyclyl-heteroalkyl, heterocyclyl-heteroalkenyl, or heterocyclyl-heteroalkynyl, non-substituted or substituted by at least one T 1 ,

wherein a carbon atom or heteroatom of said alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, arylheteroalkyl, arylheteroalkenyl, arylheteroalkynyl, cycloalkyl, heterocycle, heterocyclyl-alkyl, heterocyclyl-alkenyl, heterocyclyl-alkynyl, heterocyclyl-heteroalkyl, heterocyclyl-heteroalkenyl, or heterocyclyl-heteroalkynyl can be oxidized to form a C═O, C═S, N═O, N═S, S═O or S(O) 2 ,

wherein the aryl, arylalkyl, arylalkenyl, arylalkynyl, arylheteroalkyl, arylheteroalkenyl, arylheteroalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocycle, heterocyclyl-alkyl, heterocyclyl-alkenyl, heterocyclyl-alkynyl, heterocyclyl-heteroalkyl, heterocyclyl-heteroalkenyl, or heterocyclyl-heteroalkynyl can be fused with at least one further cycle,

and wherein said alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl-alkyl, heterocyclyl-alkenyl, or heterocyclyl-alkynyl group can include one or more heteroatoms, selected from O, S and N, in the alkyl, alkenyl, or alkynyl moiety;

R 4 represents —CN, —O-cycloalkyl, —O-cycloalkenyl, —O-cycloalkynyl, —S-cycloalkyl, —S-cycloalkenyl, —S-cycloalkynyl, C 3 -C 20 alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, —O-aryl, —S-aryl, arylalkyl, arylalkenyl, arylalkynyl, arylheteroalkyl, arylheteroalkenyl, arylheteroalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocycle, —O-heterocycle, —S-heterocycle, heterocyclyl-alkyl, heterocyclyl-alkenyl, heterocyclyl-alkynyl, heterocyclyl-heteroalkyl, heterocyclyl-heteroalkenyl, or heterocyclyl-heteroalkynyl, non-substituted or substituted by at least one T 2 ,

wherein a carbon atom or heteroatom of said alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, arylheteroalkyl, arylheteroalkenyl, arylheteroalkynyl, cycloalkyl, heterocycle, heterocyclyl-alkyl, heterocyclyl-alkenyl, heterocyclyl-alkynyl, heterocyclyl-heteroalkyl, heterocyclyl-heteroalkenyl, or heterocyclyl-heteroalkynyl can be oxidized to form a C═O, C═S, N═O, N═S, S═O or S(O) 2 ,

and wherein said alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl-alkyl, heterocyclyl-alkenyl, or heterocyclyl-alkynyl group can include one or more heteroatoms, selected from O, S and N, in the alkyl, alkenyl, or alkynyl moiety;

R 11 represents hydrogen, alkyl or aryl,

wherein a carbon atom of said alkyl or aryl can be oxidized to form a C═O, C═S, N═O, N═S, S═O or S(O) 2 ;

T 1 represents hydrogen, halogen, —OT 3 , —OCF 3 , ═O, —ST 3 , ═S, —S(O)T 4 , —S(O) 2 T 4 , —S(O) 2 NT 5 T 6 , —CF 3 , —NO 2 , —NT 5 T 6 , —NT 3 S(O) 2 T 4 , CN, —NT 3 C(O)T 4 , —NT 3 C(O)NT 5 T 6 , —C(O)OT 3 , —C(O)NT 5 T 6 , —C(O)T 4 , alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, arylheteroalkyl, arylheteroalkenyl, arylheteroalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocycle, heterocyclyl-alkyl, heterocyclyl-alkenyl, heterocyclyl-alkynyl, heterocyclyl-heteroalkyl, heterocyclyl-heteroalkenyl, or heterocyclyl-heteroalkynyl,

wherein said alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, arylheteroalkyl, arylheteroalkenyl, arylheteroalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocycle, heterocyclyl-alkyl, heterocyclyl-alkenyl, heterocyclyl-alkynyl, heterocyclyl-heteroalkyl, heterocyclyl-heteroalkenyl, or heterocyclyl-heteroalkynyl can be substituted with one or more T 7 ,

and wherein a carbon atom or heteroatom of said alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, arylheteroalkyl, arylheteroalkenyl, arylheteroalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocycle, heterocyclyl-alkyl, heterocyclyl-alkenyl, heterocyclyl-alkynyl, heterocyclyl-heteroalkyl, heterocyclyl-heteroalkenyl, or heterocyclyl-heteroalkynyl can be oxidized to form a C═O, C═S, N═O, N═S, S═O or S(O) 2 ;

T 2 represents hydrogen, halogen, —OT 8 , —OCF 3 , ═O, —ST 8 , ═S, —S(O)T 9 , —S(O) 2 T 9 , —S(O) 2 NT 10 T 11 , —CF 3 , —NO 2 , —NT 10 T 11 , —NT 8 S(O) 2 T 9 , —CN, —NT 8 C(O)T 9 , —NT 8 C(O)NT 10 T 11 , —C(O)OT 8 , —C(O)NT 10 T 11 , —C(O)T 9 , alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, arylheteroalkyl, arylheteroalkenyl, arylheteroalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocycle, heterocyclyl-alkyl, heterocyclyl-alkenyl, heterocyclyl-alkynyl, heterocyclyl-heteroalkyl, heterocyclyl-heteroalkenyl, or heterocyclyl-heteroalkynyl,

wherein said alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, arylheteroalkyl, arylheteroalkenyl, arylheteroalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocycle, heterocyclyl-alkyl, heterocyclyl-alkenyl, heterocyclyl-alkynyl, heterocyclyl-heteroalkyl, heterocyclyl-heteroalkenyl, or heterocyclyl-heteroalkynyl can be substituted with one or more T 7 ,

and wherein a carbon atom or heteroatom of said alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, arylheteroalkyl, arylheteroalkenyl, arylheteroalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocycle, heterocyclyl-alkyl, heterocyclyl-alkenyl, heterocyclyl-alkynyl, heterocyclyl-heteroalkyl, heterocyclyl-heteroalkenyl, or heterocyclyl-heteroalkynyl can be oxidized to form a C═O, C═S, N═O, N═S, S═O or S(O) 2 ;

T 3 represents hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, or heterocycle,

wherein said alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, or heterocycle can be substituted or non: substituted with one or more —OH, ═O, halogen, ═S, —CF 3 , —O-alkyl, —OCF 3 , —CN, —NO 2 , —C(O)OH, —NH 2 or C(O)NH 2 ,

and wherein a carbon atom or heteroatom of said alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, or heterocycle can be oxidized to form a C═O, C═S, N═O, N═S, S═O or S(O) 2 ;

T 4 represents —OH, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, or heterocycle,

wherein said alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, or heterocycle, can be substituted or non substituted with one or more —OH, ═O, halogen, —SH, ═S, —CF 3 , —O-alkyl, —OCF 3 , —CN, —NO 22 , —C(O)OH, —NH 2 or C(O)NH 2 ,

and wherein a carbon atom or heteroatom of said alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl aryl, or heterocycle can be oxidized to form a C═O, C═S, N═O, N═S, S═O or S(O) 2 ;

T 5 and T 6 each independently represent hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, or heterocycle

wherein said alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, or heterocycle can be substituted or non substituted with one or more —OH, ═O, halogen, —SH, ═S, —CF 3 , —O-alkyl, —OCF 3 , —CN, —NO 2 , —C(O)OH, —NH 2 or C(O)NH 2 ,

and wherein a carbon atom or heteroatom of said alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl aryl, or heterocycle can be oxidized to form a C═O, C═S, N═O, N═S, S═O or S(O) 2 ,

or T 5 and T 6 can be taken together to form a 4, 5, 6 or 7 membered heterocycle substituted or non substituted with an alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, —OH, halogen, —SH, —CF 3 , —O-alkyl, —OCF 3 , —CN, —NO 2 , —C(O)OH, —NH 2 or —C(O)NH 2 ;

T 7 represents an alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, —OH, ═O, halogen, —SH, ═S, —CF 3 , —CN, —NO 2 , —COOH, —NH 2 , or —C(O)NH 2 ;

T 8 represents hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, or heteroalkynyl, wherein said alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, or heteroalkynyl, can be substituted or non substituted with one or more —OH, ═O, halogen, —SH, ═S, —CF 3 , —O-alkyl, —OCF 3 , —CN, —NO 2 , —C(O)OH, —NH 2 or —C(O)NH 2 ,

and wherein a carbon atom or heteroatom of said alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, or heteroalkynyl can be oxidized to form a C═O, C═S, N═O, N═S, S═O or S(O) 2 ;

T 9 represents —OH, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, or heteroalkynyl, wherein said alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, or heteroalkynyl; can be substituted or non substituted with one or more —OH, ═O, halogen, —SH, ═S, —CF 3 , —O-alkyl, —OCF 3 , —CN, —NO 2 , —C(O)OH, —NH 2 or —C(O)NH 2 ,

and wherein a carbon atom or heteroatom of said alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, or heteroalkynyl can be oxidized to form a C═O, C═S, N═O, N═S, S═O or S(O) 2 ; and

T 10 or T 11 each independently represent hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, or heteroalkynyl,

wherein said alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, or heteroalkynyl, can be substituted or non substituted with one or more —OH, ═O, halogen, —SH, ═S, —CF 3 , —O-alkyl, —OCF 3 , —CN, —NO 2 , —C(O)OH, —NH 2 or —C(O)NH 2 ,

and wherein a carbon atom or heteroatom of said alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, or heteroalkynyl can be oxidized to form a C═O, C═S, N═O, N═S, S═O or S(O) 2 ,

or T 10 and T 11 can be taken together to form a 4, 5, 6 or 7 membered heterocycle substituted or non substituted with an alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, —OH, halogen, —SH, —CF 3 , O-alkyl, —OCF 3 , —CN, —NO2 2 , —C(O)OH, —NH 2 or —C(O)NH 2 ;

and a racemate, enantiomer, isomer, atropisomer or diastereoisomer or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a compound according to claim 1 as an active ingredient and a pharmaceutically acceptable carrier.

3. The pharmaceutical composition according to claim 2 further comprising a further antiviral agent.

4. A method of treatment of a viral infection comprising administering a compound according to claim 1 to a patient in need thereof.

5. The method according to claim 4 wherein said viral infection is a retroviral infection.

6. The method according to claim 5 wherein said retroviral infection is HIV.

7. A method for the treatment of an HIV infection in a mammal being infected comprising administering the pharmaceutical composition according to claim 2 .

8. A method of inhibiting the replication of HIV comprising exposing said HIV to an effective amount of a compound according to claim 1 under conditions where replication of HIV is inhibited.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 25, 2017
From: LABORATOIRE BIODIM
To: HIVIH
Reel/Frame 041075/0861 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2015
From: CHASSET, SOPHIE; CHEVREUIL, FRANCIS; LEDOUSSAL, BENOIT; LE STRAT, FRÉDÉRIC; BENAROUS, RICHARD
To: LABORATOIRE BIODIM
Reel/Frame 034904/0751 →
Priority Claims (1)
EP 11305406 · Apr 7, 2011 · regional
Continuity (2)
Provisional Application 61472809 · Apr 7, 2011
Related Publication 20140128383A1 · May 8, 2014